Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Prostate Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Prostate Cancer
    Prostate Cancer Mortality Is Higher for Overweight Men With High Insulin Secretion Prior to Diagnosis - (DGNews)
    TopAbstracts in Prostate Cancer 10/01/2008 - (DGNews)
    Hormone Therapy Before Brachytherapy May Increase Mortality in Prostate Cancer: Presented at ASTRO - (DGDispatch)
    Radiation Plus Hormone Therapy Cuts Prostate Cancer Mortality by 50%: Presented at ASTRO - (DGDispatch)
    American Urological Association Releases Best Practice Statement on Cryosurgery - (DGNews)

    News archive

     Recent webcasts/CME - Prostate Cancer

    Webcasts/CME archive

     Recent cases - Prostate Cancer
      Anejaculation as an Atypical Presentation of Prostate Cancer: A Case Report
      FDG PET-CT Demonstration of Metastatic Neuroendocrine Tumor of Prostate
      Ophthalmoplegia - An Unusual Manifestation of Metastatic Carcinoma of the Prostate
      Hypertrophic Osteoarthropathy as the Cause of a Super Scan of the Bone in a Patient with Prostate Cancer: A Case Report
      Giant Organ Confined Prostatic Adenocarcinoma: A Case Report

      Cases archive
        




      my personal edition > prostate cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Thalidomide Combination Shows Activity in Androgen-Independent Prostate Cancer: Presented at CFS

      By Charlene Laino

      NEW YORK, NY -- November 21, 2003 -- A combination of paclitaxel, estramustine and thalidomide shows activity for the treatment of chemotherapy-refractory, androgen-independent prostate cancer, a Phase II study suggests.

      This finding was presented here on November 14th at Chemotherapy Foundation Symposium XXI, by Danai Daliani, MD, medical oncologist, University of Texas M.D. Anderson Cancer Center, Houston, United States.

      The study has enrolled 30 patients with androgen-independent prostate cancer progressing after 1 or 2 prior cytotoxic treatment(s). The median age was 66 years, and the median Zubrod performance status was 1. Twenty of the men had had 1 prior chemotherapy regimen and the rest had had 2 prior regimens.

      The men were given 100 mg/m2 of paclitaxel a week, for 2 of 3 weeks; 140 mg of oral estramustine every 8 hours, 5 days a week, for 2 of 3 weeks; and escalating doses of thalidomide, starting with 200 mg a day and titrated up to 600 mg a day.

      Seventy-two percent of the 25 evaluable patients achieved a sustained decline in prostate-specific antigen levels of 50% or more, Dr. Daliani reported. Twelve percent showed a drop of 80% or more. The men who experienced a drop in PSA also reported less bone pain, she added.

      Nearly 14% of the 29 men evaluable for toxicity developed Grade 3-4 deep-vein thrombosis, despite warfarin prophylaxis, requiring treatment discontinuation in 2 of the 4 patients. Also, 2 additional patients stopped treatment due to intercurrent infection, and 1 man died from sepsis. There were no cases of grade 2-4 neuropathy.

      Noting that a clinically significant indicator of anti-tumour activity is having 30% or more patients experience at least a 50% drop in PSA levels, Dr. Daliani concluded that the results justify further study of the combination therapy in patients with androgen-independent prostate cancer.


      [Study Title: A Tolerance and efficacy Study of Thalidomide, Paclitaxel, and Estramustine for Patients with Chemotherapy Refractory Androgen Independent Prostate cancer. Abstract 48]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send